Glenmark Pharmaceuticals Share Price in Focus; Goa Facility Gets VAI Classification

Glenmark Pharmaceuticals has received the Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (U.S. FDA) for its formulations manufacturing facility in Goa.  

The facility has been classified as Voluntary Action Indicated (VAI), the company noted in a filing on September 23, 2026.  

FDA Inspection in June 

The U.S. FDA inspected Glenmark’s Goa manufacturing facility between June 22 and June 30, 2026. The company has now received the report following the inspection. 

Glenmark has not disclosed the individual observations from the inspection in its September 23 release. The filing also does not give details of any action to be taken at the facility in connection with the report.  

Goa Manufacturing Site 

The inspection relates specifically to Glenmark’s formulations manufacturing facility in Goa, India. The company has 11 manufacturing facilities spread across four continents and six R&D centres. 

Glenmark said it has a commercial presence in more than 80 countries. Its business includes branded, innovative, generic, and consumer health products, with a focus on respiratory, dermatology, and oncology.  

Glenmark’s Business 

The company’s September 23 filing was submitted to both the NSE and BSE. The company described itself as a research-led pharmaceutical business in the release.  

It also stated that Scrip 100 placed Glenmark among the Top 100 biopharmaceutical companies globally by pharmaceutical sales for 2024.  

What the Filing States 

The latest disclosure confirms the receipt of the EIR and the VAI classification for the Goa facility. No further details on the inspection findings have been provided in the release. 

Read More: Royal Orchid Hotels Share Price in Focus; Expands with New Regenta Hubballi in Karnataka! 

Glenmark Pharmaceuticals Share Price Performance  

As of September 23, 2026, 12:45 pm, Glenmark Pharmaceuticals share price was trading at ₹2,458.50, a 0.12% decrease from the previous closing price. 

Conclusion 

The report follows the U.S. FDA inspection conducted at the Goa facility in June. Glenmark has disclosed the VAI classification but has not shared the specific inspection observations. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.  

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.